About C2i Genomics
C2i Genomics is a Healthcare company based in New York (United States) founded in 2019, and was acquired by Veracyte in January 2024. Liquid biopsy for post-cancer surgery tumor monitoring is provided. C2i Genomics has raised $112 million across 2 funding rounds from investors including ARE, Veracyte and Driehaus. C2i Genomics has completed 1 acquisition, including QnA DX. C2i Genomics offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Veracyte, Inc. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
C2i Genomics was founded in 2019 and is based in New York, United States. Operations focus on the biotechnology sector, where liquid biopsy services are delivered for monitoring patients after cancer surgery. Genetic changes across tumors are detected through a specialized tool. Thousands of data points from routine blood tests are compared to tumor tissue sequences and whole-genome data using bioinformatics and AI methods.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website c2i-genomics.com
- Social LinkedIn X YouTube
- Acquired by Veracyte (Jan 2024)
- Legal Name Veracyte, Inc
Products & Services of C2i Genomics
C2i Genomics offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay.
Test for thyroid cancer detection using genomic sequencing.
Assay for prostate cancer risk assessment via genomics.
Tool for breast cancer prognosis using gene expression.
Test for bladder cancer monitoring with AI integration.
Platform for detecting residual cancer via whole-genome sequencing.
Apps and channels of C2i Genomics
its YouTube channel Veracyte has 607 subscribers and 30 videos.
Videos from C2i Genomics
The most watched videos on C2i Genomics's YouTube channel, Veracyte (607 subscribers). Click a video to play it here.
More on Veracyte.
Funding Insights of C2i Genomics
C2i Genomics has successfully raised a total of $112M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $112M
- Total Rounds 2
- Last Round Series B — $100M
- First Round $12M
(May 2020)
- Investors Count 10
All 2 funding rounds of C2i Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $100M | Series B | – | Casdin Capital | |
| May 2020 | $12M | Series A | – | Casdin Capital |
11 investors in total: 11 institutional.
Investors in C2i Genomics
C2i Genomics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Veracyte and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Venture capital firm offering funding and tools for startups in technology and investment sectors. | nfx.com | |||
Tech and life Science focused early stage VC firm investing in the US | iglobepartners.com | Singapore, Singapore | ||
Technology investing and private equity firm focused on partnerships. | silverlake.com | |||
Early-stage healthcare investments are managed by LionBird venture capital firm. | lionbird.com | Tel Aviv, Israel | ||
Tech startups are funded by S32, a venture capital entity. | s32.com | Sunnyvale, United States | ||
Fund investment management services are provided by Driehaus in Chicago. | 1982 | driehaus.com | Chicago, United States | |
Funding is provided for innovative cancer research initiatives. | themarkfoundation.org | New York, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Provider of wealth, retirement, taxation, and financial planning services | 2001 | wealthqb.com | Durham, United States |
Investor details for C2i Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of C2i Genomics
179 people are tracked at C2i Genomics (65 in leadership, 8 in board & advisors, 106 in team).
| Name | Role | Group |
|---|---|---|
Ryan Ulaszek | Senior Director, Cloud Architecture | Leadership |
Brad Meyer | Director Of Automation & Process Engineering | Leadership |
John Leite | Chief Commercial Officer | Leadership |
Paul Schock | Director Cloud Devops | Leadership |
Natalia de la Fuente | Associate Director Medical Affairs | Leadership |
Bryan Coon | Vice President, Global Digital Transformation | Leadership |
Jeremy Adams | Director - PMO | Leadership |
Christelle Lautard | Associate Director Continuous Improvement And Compliance | Leadership |
Jerome van Crayelynghe | Director, Supply Chain | Leadership |
Carlo Artieri | Executive Director Of Bioinformatics And Data Science | Leadership |
Brian Niemeyer | Director, Cloud Architecture | Leadership |
Bill Moore | Vice President, Global IT Operations | Leadership |
Roy Coren | Chief Information Security Officer | Leadership |
Irina Rosca | Executive Director Supply Chain And Operations | Leadership |
Oanh Dang | Senior Director, Corporate And Business Development | Leadership |
Timothy Barr | Director Of Market Access | Leadership |
Brad Lotterman Apr | Director Of Communications | Leadership |
Steve Place | Director, Global Marketing Operations | Leadership |
Graham Poage | Director, Market Access | Leadership |
Norah Garrett | Director, Total Rewards | Leadership |
159 more people are available in the full profile.
Complete people profiles for C2i Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by C2i Genomics
C2i Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include QnA DX.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Standalone clinical diagnostic laboratory services are operated in Cambridge. | qnadx.com | Cambridge, United States | 2018 | Mar 2021 | •••• |
Complete acquisition details for C2i Genomics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of C2i Genomics
Competitors of C2i Genomics
C2i Genomics has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of C2i Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as C2i Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about C2i Genomics
Complete news archive for C2i Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C2i Genomics
C2i Genomics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
C2i Genomics is headquartered in New York, United States. It is registered at New York, New York, United States.
C2i Genomics is a funded company, having raised a total of $112M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on May 2020.
C2i Genomics was founded in 2019 and is based in New York, United States. Operations focus on the biotechnology sector, where liquid biopsy services are delivered for monitoring patients after cancer surgery. Genetic changes across tumors are detected through a specialized tool. Thousands of data points from routine blood tests are compared to tumor tissue sequences and whole-genome data using bioinformatics and AI methods.
C2i Genomics's top competitors include Guardant Health, GRAIL and Natera.
C2i Genomics offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay.
C2i Genomics has made 1 acquisition, including QnA DX.
C2i Genomics has 11 investors. Key investors include ARE, Veracyte, Driehaus, Gordon Asset Management, and Casdin Capital.
C2i Genomics operates through Veracyte, Inc.
Yes. C2i Genomics was acquired by Veracyte in January 2024.